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Abstract 
Background: Left ventricular (LV) hypertrophy (LVH) in uncontrolled hypertension is an independent predictor of 
mortality, though its regression with treatment improves outcomes. Retrospective data suggest that early control of 
hypertension provides a prognostic advantage and this strategy is included in the 2018 European guidelines, which 
recommend treating grade II/III hypertension to target blood pressure (BP) within 3 months. The earliest LVH regres-
sion to date was demonstrated by echocardiography at 24 weeks. The effect of a rapid guideline-based treatment 
protocol on LV remodelling, with very early BP control by 18 weeks remains controversial and previously unreported. 
We aimed to determine whether such rapid hypertension treatment is associated with improvements in LV structure 
and function through paired cardiovascular magnetic resonance (CMR) scanning at baseline and 18 weeks, utilising 
CMR mass and feature tracking analysis.
Methods: We recruited participants with never-treated grade II/III hypertension, initiating a guideline-based treat-
ment protocol which aimed to achieve BP control within 18 weeks. CMR and feature tracking were used to assess 
myocardial morphology and function immediately before and after treatment.
Results: We acquired complete pre- and 18-week post-treatment data for 41 participants. During the interval, LV 
mass index reduced significantly (43.5 ± 9.8 to 37.6 ± 8.3 g/m2, p < 0.001) following treatment, accompanied by 
reductions in LV ejection fraction (65.6 ± 6.8 to 63.4 ± 7.1%, p = 0.03), global radial strain (46.1 ± 9.7 to 39.1 ± 10.9, 
p < 0.001), mid-circumferential strain (− 20.8 ± 4.9 to − 19.1 ± 3.7, p = 0.02), apical circumferential strain (− 26.0 ± 5.3 
to − 23.4 ± 4.2, p = 0.003) and apical rotation (9.8 ± 5.0 to 7.5 ± 4.5, p = 0.003).
Conclusions: LVH regresses following just 18 weeks of intensive antihypertensive treatment in subjects with newly-
diagnosed grade II/III hypertension. This is accompanied by potentially advantageous functional changes within the 
myocardium and supports the hypothesis that rapid treatment of hypertension could improve clinical outcomes.
Trial registration: ISRCTN registry number: 57475376 (assigned 25/06/2015).
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Background
Hypertension is associated with disruption of the 
structure and function of the left ventricular (LV) 
myocardium. Foremost amongst these changes is LV 
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hypertrophy (LVH), quantified as LV mass (LVM) and 
normalised to body surface area (BSA) as LVM index.
Increased LVM has been shown to be an independ-
ent predictor of mortality in the Framingham cohort 
[1]. Further cohort studies have demonstrated that LVM 
also stratifies risk in subjects with and without coronary 
artery disease [2] and specifically in the hypertensive 
population [3].
Following treatment of hypertension, persistent LVH 
is an indicator of poor prognosis, whereas complete 
regression almost normalises cardiovascular risk [4]. The 
association of treatment-induced LVM regression with 
favourable prognosis is independent of baseline LVM and 
degree of blood pressure (BP) reduction [5]. As a measure 
of end-organ damage, LVM may be more closely linked to 
prognosis than office BP reductions [6], though low event 
rates in cohort studies of uncomplicated essential hyper-
tension hamper definitive conclusions as to the relative 
weighting of these associations [4–7]. The timing of LVH 
regression is also unclear, with the most rapid improve-
ment demonstrated in a longitudinal study of 24 weeks’ 
duration using echocardiography to quantify LVM before 
and after treatment for patients enrolled with grade I or 
II hypertension (mean baseline office BP: 164/93mmHg) 
and receiving either standard BP management or inten-
sive management within the study [8].
LVH in hypertension allows the heart to maintain 
a normal, or even supra-normal LV ejection fraction 
(LVEF) in the face of increased afterload [9], at least in 
the early stages of the disease. However, despite a nor-
mal LVEF, systolic function is demonstrably not normal 
in hearts of hypertensive patients. Cross-sectional echo-
cardiographic studies using speckle tracking have shown 
a reduction in measures of myocardial strain (deforma-
tion per unit length) in hypertensive individuals ver-
sus normotensive control subjects [10–12], which can 
be described according to the direction of deformation 
relative to the cardiac axis (Fig.  1). In individuals with 
hypertension, speckle tracking has demonstrated a 
reduction in myocardial global longitudinal strain (GLS) 
and global radial strain (GRS) [10, 11]. Analysis of cir-
cumferential strain magnitude in hypertensive subjects 
have been inconsistent, with some studies suggesting 
a reduction in global circumferential strain (GCS) in 
hypertension [10] and others determining no significant 
difference compared with normotensive controls [11, 12].
LV torsion, defined as the relative systolic twisting 
motion as a consequence of basal clockwise rotation and 
apical anticlockwise rotation normalised to LV length 
[13], has been shown to increase in amplitude in hyper-
tensive subjects when measured using echocardiographic 
speckle tracking [10] and cardiovascular magnetic reso-
nance (CMR) imaging [14]. This may, at least in part, 
facilitate the preservation of LVEF seen in hypertensive 
subjects despite the reduction in longitudinal and radial 
strain [14].
Resolution of LV systolic dysfunction, defined accord-
ing to GLS, GCS and GRS, in subjects with treated 
hypertension when compared with untreated hyperten-
sion and normotensive controls has been demonstrated 
in a cross-sectional study [10]. Longitudinal studies 
investigating the effect of antihypertensive treatment on 
LV myocardial mechanics have concentrated on circum-
ferential and longitudinal strain [15, 16] or longitudinal 
strain alone [8]. The effects of antihypertensive treatment 
on radial strain and LV torsion have not been reported in 
longitudinal studies. Furthermore, the shortest duration 
of antihypertensive treatment shown to improve longitu-
dinal and circumferential strain is 24 weeks, within the 
study design described above and including a heteroge-
nous cohort of participants treated either with intensive 
management or standard care [8].
CMR has been shown to have greater accuracy in 
the measurement of LVM when compared with 2D 
Fig. 1 Schematic representation of strain parameters in relation to the LV myocardium
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echocardiography [17]. CMR feature tracking for strain 
assessment, which uses post-processing technology to 
track intramyocardial features throughout the cardiac 
cycle [18], has been shown to be more reproducible than 
older CMR techniques [19].
This study therefore aims to use CMR to establish for 
the first time whether LVH regression occurs within 18 
weeks of commencing antihypertensive treatment in 
individuals with never-treated essential hypertension. 
Furthermore, CMR feature tracking will supplement 
this through a comprehensive assessment of myocardial 
strain in all planes relative to the cardiac axis: the first 
time that this technology has been applied in a longitu-
dinal study, determining the cardiac effects of antihyper-
tensive treatment with greater accuracy than previous 
studies using echocardiography.
Methods
Potential participants aged 18–79 years and never treated 
for hypertension were identified by their usual care cli-
nician following an office systolic BP of ≥170mmHg. 
Ambulatory monitoring was then used to confirm at 
least grade II hypertension (daytime average systolic BP 
≥150 mmHg) prior to enrolment.
Exclusion criteria were: renal impairment (eGFR < 60 
ml/min/1.73   m2, Hemoglobin <10 g/dl, platelet count 
<100 ×  109/l or bleeding diathesis, pregnancy or breast-
feeding, inability to provide informed consent, hyper-
tension-related event (including stroke or acute kidney 
injury) within the preceding 3 months, or any condition, 
including hypertensive urgency, requiring immediate BP 
lowering or tailored antihypertensive strategy.
Participants underwent a treatment programme 
involving fortnightly nurse-led consultations. At each 
consultation stepwise intensification of antihyperten-
sive treatment or further investigation was mandated for 
those not at office BP target according to a pre-defined 
protocol, as detailed previously [20]. Treatment targets 
and antihypertensive medication followed national and 
international consensus guidelines [21, 22].
CMR studies were undertaken immediately before 
and after 18 weeks’ antihypertensive treatment. Imag-
ing was performed at the Exeter Magnetic Resonance 
Research Centre, St Luke’s Campus, University of Exeter 
using a 1.5T CMR system (Intera, Philips Healthcare, 
Best, Netherlands) with a 5-channel surface phased array 
coil. Our standard clinical hypertension CMR protocol 
was undertaken which includes 4-chamber, 2-chamber, 
3-chamber and short axis stack balanced steady-state 
free precession cine imaging (balanced fast field gradient 
echo sequences, repetition time 3.2 ms, echo time 1.6 ms, 
20–30 phases, slice thickness 8 mm, 1.2 × 1.2 mm spatial 
resolution). T1-weighted gradient echo sequences were 
used to determine renal and adrenal anatomy, followed 
by aortic and renal artery delineation using early gado-
linium enhancement (0.15  mmol/kg gadopentate dime-
glumine, Gadovist®, Bayer Healthcare Berlin, Germany), 
(repetition time 5.2 ms, echo time 1.5 ms, 40 slices, 8 mm 
slice thickness, 0.7 × 0.7  mm spatial resolution). Late 
gadolinium enhancement (LGE) gradient echo phase-
sensitive inversion recovery sequences performed 8–10 
min after gadolinium administration were acquired in 
three short axis slices and a long axis plane to assess for 
myocardial fibrosis or infiltration before and after antihy-
pertensive treatment (repetition time 5.4  ms, echo time 
2.6 ms, 8 mm slice thickness, 1.2 × 1.2 mm spatial resolu-
tion). This ensured that it would be possible to exclude 
other causes of LVH, such as Anderson-Fabry disease 
and amyloidosis, together with prior myocardial infarc-
tion, which could affect the volumetric and feature track-
ing analysis.
Post-hoc CMR data analysis was conducted by a single 
operator. LV volumes and LVM were calculated through 
planimetry of end-diastolic epicardial areas and end-dias-
tolic and end-systolic endocardial areas for each short 
axis slice covering the entire left ventricle from mitral 
valve to apex, in line with standard protocols [23] and 
using commercially-available software (Extended MR 
WorkSpace, Philips Healthcare). Left atrial (LA) volume 
was determined using the biplane area length method 
[24]. LV long-axis length was assessed in a 4-chamber 
view by measuring the distance from the middle of the 
atrioventricular ring to the apex at end-diastole. Short-
axis length was assessed in the same view at the papillary 
muscle insertion point. LV sphericity index was defined 
as the ratio of LV short axis length to long axis length and 
LV thickness was measured in the short axis at papillary 
muscle level in end-diastole.
Feature tracking analysis required dedicated software 
(TomTec Imaging Systems, 2-dimensional CPA MR, 
Cardiac Performance Analysis, Unterschleissheim, Ger-
many). Short axis basal, mid-ventricular and apical image 
plane selection was determined as previously described 
[25]. LV endocardial and epicardial borders were manu-
ally traced with the initial contour set in end-diastole. 
The software then automatically traced the tissue voxels 
throughout the cardiac cycle, which was reviewed and 
repeated if myocardial tracking was not adequate visually.
Basal clockwise rotation (φbase), apical anticlockwise 
rotation (φapex) and the distance between the basal and 
apical imaging planes (D) were used to derive twist and 
torsion:
Twist = φapex−φbase
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Study endpoints
The aim of the CMR investigation was to determine 
whether LVM index changed following 18 weeks of antihy-
pertensive treatment.
Key further endpoints were the change in LV volume, 
LVEF, sphericity index, LA volume and strain parameters 
with treatment. The presence and distribution of LGE in 
our cohort was also evaluated, together with the incidence 
of detection of secondary causes of hypertension.
Sample size and statistical analysis
A previous study assessing the change in CMR-defined 
LVM index with antihypertensive treatment found a mean 
reduction from 80.3 ± 15.7  to 70.1 ± 16.7  g/m2 after 52 
weeks of treatment with a combination of an angiotensin 
converting enzyme inhibitor and calcium channel blocker 
[26]. An effect size of at least a 0.65 standard deviation dif-
ference in LVM index before and after antihypertensive 
treatment was therefore used to inform our study sample 
size given our study has a shorter intervention period but 
uses a technique better able to detect smaller changes in 
LVM.
We planned to enroll 50 participants into a clinical study 
of the feasibility and safety of rapid treatment of grade II/
III hypertension [20]. Of these, 75% recruitment to paired 
CMR studies was anticipated. Using a two-tailed paired 
t-test (α = 0.05) comparison, 38 participants would enable 
the detection of a 0.55 SD with 90% power at a level of sig-
nificance of 5%.
Statistical analysis was performed using STATA (version 
14.1, StataCorp, College Station, Texas, USA). Baseline and 
outcome data are presented as means (± standard devia-
tion) or medians (interquartile range) for continuous data 
depending on the normality of the data and counts (per-
centages) for categorical and binary variables.
Parametric data were analysed using a paired t-test, 
non-parametric data were analysed using Wilcoxon’s 
signed ranks test and proportions using a one-sample test 
of proportions. A two-sided P value threshold <0.05 was 
considered statistically significant. Univariate linear regres-
sion models were employed to determine the relationship 
between BP response during the study and markers of 
change in LV structure and function as outcome variables.
Results
Of the 55 participants recruited to the study, one did not 
complete the treatment protocol and nine did not com-
plete 2 CMR studies due to claustrophobia. For two addi-




two patients were unable to attend their final appoint-
ments. The following results therefore refer to the 
remaining 41 participants (Fig. 2).
Median age of the analysis group was 59 years, 61% 
were male, there were no diabetic subjects and mean 
office BP reduced from 175/103 to 132/80  mmHg with 
treatment. Further characteristics prior to and following 
the treatment programme are summarised (Table 1).
Left ventricular mass and mass index
LVM index reduced significantly after 18 weeks of anti-
hypertensive treatment (43.5 ± 9.8 to 37.6 ± 8.3g/m2, 
p < 0.001). This marked reduction was also observed 
in non-indexed LVM (88.9 ± 24.5 to 76.8 ± 21.7  g, 
p < 0.001) (Fig. 3) and LV diastolic thickness (12.2 ± 2.0 to 
10.5 ±1.6 mm, p < 0.001).
Change in LVM index was associated with diastolic BP 
change (β = 0.4, p = 0.01), and with systolic BP change (β 
= 0.3, p = 0.04).
Likewise, non-indexed LVM regression was associated 
with office diastolic BP change after 18 weeks of antihy-
pertensive treatment (β = 0.4, p = 0.01). Non-indexed 
LVM regression was also associated with office systolic 
BP change over 18 weeks (β = 0.3, p = 0.04).
Left ventricular and left atrial volumes
LV and LA volumes and derived parameters are given in 
(Table 2).
Over 18 weeks, LV end-diastolic volume (LVEDV) and 
LVEDV index reduced significantly whereas LV end-
systolic volume (LVESV) and LVESV index increased 
Fig. 2 Number of enrolled participants in the clinical study of rapid 
hypertension treatment with MR imaging appropriate for analysis
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significantly following antihypertensive treatment. In 
accordance with this, stroke volume reduced over the 
study period, as did LVEF. There was no significant 
change in LA volume.
When participants prescribed β-blockers were 
excluded from the analysis, changes in LVESV and 
LVESV index were no longer significant, though the find-
ing of significant reductions in LVEDV, LVEDV index, 
LVEF and stroke volume persisted. In addition, sub-
group analyses were conducted for each class of medica-
tion, with no new significant results found.
Left ventricular strain before and after antihypertensive 
treatment
Feature tracking analysis of all CMR study participants 
revealed the reduction in global LVEF and stroke volume 
following antihypertensive treatment was predominantly 
linked to a significant reduction in radial strain (meas-
ured in the short axis view), a reduction in mid to apical 
circumferential strain and a reduction in apical rotation 
(Table  3, Fig.  4). Longitudinal strain trended towards 
increasing with treatment, whereas torsion tended to 
decrease with treatment, though these changes were not 
statistically significant.
Change in mean radial strain measured in the short 
axis was not significantly associated with change in 
systolic BP (β = 0.05, p = 0.8) or diastolic BP (β = 0.2, p 
= 0.2) over the 18-week study period.
Late gadolinium enhancement in treatment‑naïve 
moderate‑severe hypertension
30 participants underwent LGE imaging at baseline, the 
remaining 11 CMR participants either declining this 
aspect of the imaging protocol or not receiving contrast 
due to equipment failure. Seven (23%) were found to have 
myocardial LGE. The most frequent segment affected 
was the basal inferoseptum (71%), with the remainder 
affecting exclusively the basal inferior or basal inferolat-
eral segments. In those with basal inferoseptal or basal 
inferior LGE, Anderson-Fabry disease was excluded 
through measurement of serum α-galactosidase.
All LGE was subepicardial in distribution and there-
fore not indicative of underlying coronary artery disease. 
There were no significant changes in LGE pattern in any 
participants after 18 weeks.
Discussion
This is the first study to examine the effect on myocardial 
structure and function of a rapid, 18-week, intensive anti-
hypertensive treatment strategy. Using CMR, our study 
demonstrates that LVH regresses rapidly after only 18 
weeks intensive antihypertensive treatment and that this 
Table 1 Characteristics of participants before and after 18 weeks’ antihypertensive treatment
Expressed as mean ± standard deviation or median and interquartile range
BMI body mass index, BP blood pressure, HbA1c haemoglobin A1c
a Wilcoxon’s signed ranks test
b One-sample test of proportions
Variable Before treatment After treatment P value
Office systolic BP (mmHg) 174 ± 15.7 132 ± 11.9  < 0.001
Office diastolic BP (mmHg) 103 ± 9.3 80 ± 8.4  < 0.001
Daytime average systolic BP (mmHg) 163 ± 10.4 134 ± 10.4  < 0.001
Daytime average diastolic BP (mmHg) 93 ± 8.9 78 ± 6.8  < 0.001
Heart rate (bpm) 71 ± 12.0 64 ± 10.1  < 0.001a
BMI (kg/m2) 29.7 ± 5.3 29.7 ± 4.9 0.9
Current smoker (n) 5 (12%) 5 (12%) 1.0b
Alcohol (units/week) 8 (1–18) 9 (1–15) 0.8a
Fasting total cholesterol (mmol/L) 5.6 ± 1.2 5.6 ± 1.3 0.7
Creatinine (μmol/L) 75 ± 13.0 78 ± 13.4 0.3
HbA1c (mmol/mol) 38 ± 0.5 38 ± 0.6 0.6
Angiotensin receptor blocker (n) 0 37 (90%) n/a
Calcium channel blocker (n) 0 40 (98%) n/a
Thiazide diuretic (n) 0 24 (59%) n/a
Aldosterone antagonist (n) 0 9 (21%) n/a
α-blocker (n) 0 1 (2%) n/a
β-blocker (n) 0 3 (7%) n/a
Number of anti-hypertensives (n) 0 3 (2–3) n/a
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is associated with further, potentially beneficial, altera-
tions in cardiac physiology.
Prior to the current study, the most rapid observed 
regression of LVH during hypertension treatment was 
measured at 24 weeks [8] and this study therefore adds 
credence to the proposal in recent consensus guidelines 
that benefits can be gained from aiming to control BP in 
a shorter timeframe than 24 weeks for grade II–III hyper-
tension [27]. Furthermore, the novel use of CMR feature 
tracking in assessing all directional components of myo-
cardial deformation in a longitudinal study before and 
after the introduction of antihypertensive agents has for 
the first time found that radial strain reduces with treat-
ment, whilst also confirming the previously described 
higher longitudinal strain, lower mid and apical circum-
ferential strain and lower apical torsion in treated hyper-
tension compared with untreated hypertension [8, 10, 15, 
16].
The 2018 European Society of Hypertension  guide-
lines for the treatment of hypertension recommend that 
patients with grade II-III hypertension are treated to 
target within 3 months in order to improve prognosis 
[27]. The proposed prognostic benefit for rapid treat-
ment of hypertension is supported by observational evi-
dence from clinical records demonstrating that a delay in 
achieving target BP is associated with adverse outcomes 
[28, 29]. Additionally, retrospective analyses of major 
hypertension trials have revealed that early and effective 
BP treatment reduces subsequent adverse events with 
an apparent legacy effect beyond the period of treat-
ment delay [30, 31]. In the present study, a 14% reduc-
tion in LVM index was observed, as compared with a 17% 
reduction in LVM index found in the losartan treatment 
arm of the LIFE study [32] and the 8% reduction in LVM 
index detected in a study of intensive antihypertensive 
treatment delivered over 24 weeks [8]. The rapid reversal 
of LVH demonstrated by this study may suggest one of 
the mechanisms by which improved prognosis could be 
gained and indicate that an appropriately-designed ran-
domised controlled trial should be considered to examine 
this.
The current study also explores functional changes 
in the myocardium following antihypertensive treat-
ment, demonstrating that supra-normal LVEF is reduced 
A
B
Fig. 3 Left ventricular (LV) mass (A) and mass index (B) before and 
after 18 weeks’ antihypertensive treatment
Table 2 Left ventricular (LV) and left atrial (LA) dimensions and derived parameters determined by CMR imaging before and after 
18 weeks’ antihypertensive treatment
Expressed as mean ± standard deviation
a Wilcoxon’s signed ranks test
Variable Before treatment After treatment P value
LV end-diastolic volume (ml) 130.7 ± 28.0 125.4 ± 25.7  < 0.001
LV end diastolic volume index (ml/m2) 64.4 ± 12.0 61.8 ± 10.8  < 0.001
LV end-systolic volume (ml) 45.8 ± 16.6 46.7 ± 15.9 0.04
LV end-systolic volume index (ml/m2) 22.6 ± 8.0 23.1 ± 7.7 0.04
LV stroke volume (ml) 84.9 ± 16.5 78.6 ± 14.4  < 0.001
LV ejection fraction (%) 65.6 ± 6.8 63.4 ± 7.1 0.03
LV sphericity index 0.6 ± 0.05 0.6 ± 0.06 0.2
LA volume (ml) 73.3 ± 19.9 68.9 ± 18.5 0.2a
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by treatment, predominantly as a result of a reduc-
tion in LVEDV. Although it could be argued that the 
negative inotropic effect of β-blockade could influence 
these results, it was noted that the statistically signifi-
cant observation persists when participants receiving 
β-blockers at week 18 are excluded from the analysis. 
LV stroke volume was also found to be lower following 
antihypertensive treatment in the present study, despite 
the fact that untreated hypertension has been found to be 
associated with a lower stroke volume when compared 
with normotensive control subjects [33]. We propose 
that this finding is related to the pharmacological effects 
of antihypertensive agents used within the treatment 
protocol, with both angiotensin receptor blockers and 
diuretics likely to confer a reduction in stroke volume.
This study also shows a reduction in radial strain with 
treatment (when measured in the short axis), a finding 
which has not previously been demonstrated. This reduc-
tion in radial strain is in keeping with the demonstrated 
reduction in LVEDV with treatment and Starling’s Law, 
though discrepant with previous cross-sectional data 
using echocardiographic techniques, which suggested a 
lower radial strain in untreated hypertension when com-
pared with normotensive controls [10, 11] and subjects 
with treated hypertension [10]. This difference compared 
with previous studies may relate to the variance in imag-
ing modalities used to assess radial strain, with the CMR-
based technique used in our study known to be more 
accurate than the echocardiography techniques used in 
comparable studies. Moreover, the cross-sectional study 
designs used by previous studies are susceptible to inter-
group confounding variables, present to a lesser extent in 
our longitudinal study design.
Table 3 Left ventricular strain before and after 18 weeks’ antihypertensive treatment
Expressed as mean ± standard deviation
Strain parameter (m/m) Before treatment After treatment P value
Radial strain (short axis)
 Endocardial 48.5 ± 18.2 41.7 ± 19.7  < 0.001
 Mean 46.1 ± 9.7 39.1 ± 10.9  < 0.001
Radial strain (long axis)
 Endocardial 29.0 ± 9.2 27.4 ± 9.6 0.4
 Mean 29.0 ± 9.2 27.4 ± 9.6 0.4
Longitudinal strain
 Endocardial − 20.3 ± 5.3 − 21.0 ± 6.0 0.4
 Mean − 19.1 ± 4.7 − 19.4 ± 5.4 0.6
Basal circumferential strain
 Endocardial − 28.7 ± 4.7 − 27.6 ± 4.5 0.1
 Mean − 20.4 ± 3.9 − 19.9 ± 3.4 0.4
Mid circumferential strain
 Endocardial − 29.9 ± 6.5 − 27.0 ± 5.2 0.003
 Mean − 20.8 ± 4.9 − 19.1 ± 3.7 0.02
Apical circumferential strain
 Endocardial − 35.6 ± 6.9 − 32.0 ± 5.9 0.001
 Mean − 26.0 ± 5.3 − 23.4 ± 4.2 0.003
Rotation (apical)
 Endocardial 11.9 ± 6.7 9.4 ± 6.0 0.02
 Mean 9.8 ± 5.0 7.5 ± 4.5 0.003
Rotation (basal)
 Endocardial 3.9 ± 3.7 3.8 ± 2.9 0.9
 Mean 3.1 ± 2.6 2.8 ± 2.0 0.5
Twist
 Endocardial 15.7 ± 7.6 13.2 ± 6.3 0.03
 Mean 12.8 ± 5.9 10.4 ± 4.6 0.006
Torsion
 Endocardial 5.4 ± 3.0 4.9 ± 2.8 0.3
 Mean 4.4 ± 2.4 3.8 ± 2.0 0.2
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Our finding of reduced radial strain following anti-
hypertensive treatment may relate to the concurrent 
reduction in LV radial thickness also observed, as LVH 
has previous been demonstrated to be associated with 
increased radial strain [34]. Alternatively, this find-
ing may be a product of the unique population studied 
compared with previous investigations (treatment-naïve 
grade II-III hypertension) or an early response to treat-
ment, which then reverses. To study the possibility of the 
latter explanation, additional imaging of participants at a 
later timepoint in their treatment would be informative.
Longitudinal strain tended to increase with treatment 
of hypertension, which is in keeping with previous cross-
sectional and longitudinal studies [8, 10]. In our study, 
this increase in longitudinal strain did not reach statisti-
cal significance, though this is likely to be due to the fact 
that we found this measurement to be highly variable in 
untreated hypertension.
We also demonstrated a reduction in circumferential 
strain in the mid and apical segments in response to anti-
hypertensive treatment. As with previous studies, func-
tional disruption of the heart when exposed to increased 
afterload appears to affect apical segments to a greater 
extent than basal segments [10]. This was also the case in 
the analysis of LV rotation, with increased apical torsion 
in untreated hypertension compared with treated hyper-
tension in keeping with a previous cross-sectional study 
[10]. As expected, this translated to increased LV twist 
in untreated hypertension, though the difference became 
statistically insignificant when corrected for LV length. 
This may be due to the reduction in LV length in treated 
hypertension, as shown by the reduction in LVEDV, 
which would tend to reduce the torsion measurement.
In addition to myocardial changes with treatment, our 
protocol aimed to characterise the presence of focal fibro-
sis within the myocardium in hypertensive heart disease, 
as determined using LGE. This identified non-ischaemic 
focal fibrosis in the myocardium of 23% participants, 
with predilection for affecting the basal infero-septal seg-
ment, in agreement with previous observational studies 
of similar patient groups [35–37].
Fig. 4 Radial strain (measured in the short axis) (A), mid-circumferential strain (B), apical circumferential strain (C) and apical rotation (D) before and 
after 18 weeks of antihypertensive treatment
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Limitations
The observations in this study are based on a broad 
range of antihypertensive medication, as dictated by the 
treatment protocol and reported in Table  1. Although 
a meta-analysis has shown some variability in effect on 
LVM index between different classes of antihypertensive 
agents [38], these heterogeneities appear to be relatively 
small when only the classes of agents recommended in 
the most recent consensus guideline iterations are con-
sidered. It is unknown, however, if there is heterogeneity 
in the functional response of the myocardium to differ-
ent antihypertensive agents, though the majority of par-
ticipants in our study received the standard combination 
of renin-angiotensin axis blockade and calcium-channel 
blocker with or without the addition of a thiazide diu-
retic, ensuring that our results are translatable to clinical 
patients.
In terms of LGE, this relies on visual determination 
of the inversion time based on nulling of the “normal” 
myocardium. If diffuse myocardial fibrosis occurs in 
hypertension, this would not be visualised if the process 
homogeneously affects the whole heart and therefore 
would not have been detected by our CMR protocol, a 
limitation of the study. However, diffuse fibrosis can be 
detected using T1 mapping and this has previously been 
utilised in participants with essential hypertension [36], 
revealing no significant myocardial fibrosis between the 
groups of treated hypertensive patients (mean office BP: 
152/88  mmHg) versus normotensive controls (mean 
office BP: 123/74  mmHg). However, this study found a 
significant degree of diffuse fibrosis in the subgroup of 
patients with LVH. As LVH regresses with antihyper-
tensive treatment, it can be postulated that this group 
of patients reflects those with poorly-controlled hyper-
tension. As such, diffuse fibrosis may be a feature of 
uncontrolled hypertension, which would have not been 
evident in our study in the absence of T1 mapping. Fur-
ther investigation for diffuse fibrosis using T1 mapping in 
grade II/III uncontrolled hypertension may therefore be 
warranted.
There were 16% of  subjects enrolled in the treatment 
programme  who could not undergo CMR testing as a 
consequence of claustrophobia, which is a higher pro-
portion than would be expected. This may relate to the 
larger body habitus of participants compared to the pop-
ulation average, particularly when considered alongside 
the 60cm bore size of the CMR hardware. In addition, 
the study protocol dictated that CMR examinations were 
performed after a significant number of microvascular 
investigations, which may have led to fatigue amongst 
participants, contributing to aborted examinations.
Conclusions
The present study demonstrates rapid improvement in 
LVH as a consequence of implementation of an inten-
sive antihypertensive treatment protocol. These struc-
tural changes are accompanied by functional changes in 
the heart which include a reduction in LVEDV, radial 
strain, mid and apical circumferential strain and apical 
rotation.
Given the improved structural and functional param-
eters seen on CMR following a relatively short period of 
antihypertensive treatment for newly diagnosed hyper-
tension, early and aggressive treatment of hypertension 
could plausibly lead to improved clinical outcomes. In 
the absence of a dedicated randomised clinical trial, these 
data support a strategy of early blood pressure control, as 
recommended in the latest European Society of Hyper-
tension guidelines [27].
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